[Suppressive effect of roxithromycin on the induction of IL-2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma].
Roxithromycin (RXM) is a new macrolide antibiotics, with anti-allergic properties, the mechanisms of which action has not been well understood. The effect of RXM-treatment on the induction of interleukin 2 (IL-2) responsiveness by Dermatophagoides farinase (Df)-stimulated lymphocytes was studied in patients with bronchial asthma. RXM alone has almost no effect on lymphocyte activation. Patient's lymphocytes treated with 10 to 400 micrograms/ml doses of RXMs failed to generate Df-induced IL-2 responsiveness in a dose-dependent manner. The target cells for suppressive effect of RXM were antigen-presenting cells such as macrophages and dendritic cells rather than responder T cells. PPD-induced IL-2 responsiveness was also suppressed by the treatment, but the Con A-induced response was not. The results suggest that RXM is a slight immunosuppressant to block the induction of IL-2 responsiveness by Df-stimulated patient's lymphocytes, resulting in the interruption of a cytokine cascade of allergic responses.
Nakajima
T
T
Department of Pediatrics, Saitama Medical School, Japan.
Yoshizawa
I
I
Kawano
Y
Y
Noma
T
T
D000938:Antigen-Presenting Cells / Q000276:immunology; D039741:Antigens, Dermatophagoides; D001249:Asthma / Q000276:immunology*; D006023:Glycoproteins / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000276:immunology*; D008213:Lymphocyte Activation; D015575:Roxithromycin / Q000494:pharmacology*
D039741:Antigens, Dermatophagoides; D006023:Glycoproteins; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015575:Roxithromycin